Literature DB >> 11694685

A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital.

G W 't Jong1, A G Vulto, M de Hoog, K J Schimmel, D Tibboel, J N van den Anker.   

Abstract

BACKGROUND: The treatment of pediatric patients with drugs in hospitals is being impeded by a shortage in the availability of licensed drugs in an appropriate formulation. We have studied the extent of use of drugs that are not licensed for use in children (unlicensed) and drugs that are used outside the terms of the product license (off-label). We conducted this study in a Dutch academic children's hospital.
METHODS: In a prospective study of 5 weeks' duration, we reviewed drug prescriptions in a pediatric ward and 3 intensive care units. We classified the prescribed drugs in 3 main categories-licensed, unlicensed, and off-label-and determined the nature of their unlicensed and off-label use.
RESULTS: Two thousand one hundred thirty-nine courses of drugs were administered to 237 patients in 442 patient-days. Of 2139 prescriptions, 725 (34%) were licensed, 1024 (48%) were unlicensed, and 390 (18%) were off-label. In 392 (90%) of 435 patient-days, children received 1 or more courses of an unlicensed or off-label drug prescription in hospital.
CONCLUSION: With regard to the availability of drugs of proven quality and adequate license for pediatric patients in hospital, dramatic shortcomings exist. As a result, drug legislation originally designed to protect patients and prescribing physicians against unsafe drug use and unjustified claims has turned into an insurmountable threshold to make proper drugs available for a vulnerable minority of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694685     DOI: 10.1542/peds.108.5.1089

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  50 in total

1.  Unlicensed and off label prescription of drugs to children: population based cohort study.

Authors:  Geert W 'T Jong; Ingo A Eland; Miriam C J M Sturkenboom; John N van den Anker; Bruno H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

2.  Making medicines that children can take.

Authors:  A J Nunn
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

3.  Off-label antibiotic use in children in three European countries.

Authors:  Alessandro Porta; Susanna Esposito; Esse Menson; Nikos Spyridis; Maria Tsolia; Mike Sharland; Nicola Principi
Journal:  Eur J Clin Pharmacol       Date:  2010-06-08       Impact factor: 2.953

4.  Off-label prescribing in oncology.

Authors:  Susan G Poole; Michael J Dooley
Journal:  Support Care Cancer       Date:  2004-02-18       Impact factor: 3.603

5.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

6.  Unlicensed and off-label use of medicines in children admitted to the intensive care units of a hospital in Malaysia.

Authors:  Jian Lynn Lee; Adyani Md Redzuan; Noraida Mohamed Shah
Journal:  Int J Clin Pharm       Date:  2013-12

Review 7.  Off licence and off label prescribing in children: litigation fears for physicians.

Authors:  P Hill
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

8.  Unlicensed and off-label use of medicines at a neonatology clinic in Italy.

Authors:  Maria Dell'Aera; Anna Rita Gasbarro; Margherita Padovano; Nicola Laforgia; Donatella Capodiferro; Biagio Solarino; Roberto Quaranta; Alessandro S Dell'Erba
Journal:  Pharm World Sci       Date:  2007-03-10

9.  Drug labeling and exposure in neonates.

Authors:  Matthew M Laughon; Debbie Avant; Nidhi Tripathi; Christoph P Hornik; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith; William Rodriguez
Journal:  JAMA Pediatr       Date:  2014-02       Impact factor: 16.193

10.  No child left behind: Enrolling children and adults simultaneously in critical care randomized trials.

Authors:  Scott D Halpern; Adrienne G Randolph; Derek C Angus
Journal:  Crit Care Med       Date:  2009-09       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.